Loading clinical trials...
Loading clinical trials...
A Phase II Study of Combinations of Dendritic Cells and Cytokine-induced Killer Cell （D-CIK) Immunotherapy And Anti-Programmed Death-1 In Refractory Solid Tumors
Conditions
Interventions
D-CIK and anti-PD-1 antibody
Locations
1
China
Sun Yat-Sen University, Cancer Center
Guangzhou, Guangdong, China
Start Date
July 1, 2016
Primary Completion Date
September 1, 2019
Completion Date
October 1, 2019
Last Updated
September 1, 2016
NCT06066138
NCT06345508
NCT00026884
NCT07061964
NCT03375307
NCT04235764
Lead Sponsor
Sun Yat-sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions